Laure Bindels and her team showed that altered hepatic AHR receptor signalling could promote liver disorders in cancer cachexia, a syndrome that induces weight loss, muscle wasting and immune deficiency.

Amandine Everard's team demonstrated a causal link between the intestinal microbiota, and more precisely a phenolic metabolite produced by it, and compulsive eating behaviours.

Ana Beloqui and her team developed an oral formulation, based on lipid nanoparticles, of drugs usually administered by subcutaneous injection in the treatment of non-alcoholic fatty liver disease.

Cédric Blanpain's team discovered that RHOJ allows cancer cells with EMT to resist chemotherapy.

Thomas Marichal and his team have discovered that blood monocytes, previously considered to be differentiated cells, are in fact capable of proliferating to replace tissue macrophages.

Jean-François Collet and colleagues discovered that the chaperone GroEL works with CnoX, a chaperedoxin that controls the redox quality of GroEL substrates.

Decio L. Eizirik is the recipient of the prestigious George Eisenbarth Memorial Lecture that will be delivered at the 15th annual Network for Pancreatic Organ Donors with Diabetes (nPOD) meeting in Florida, USA.

The WEL Research Institute is #hiring a dynamic Business Development Manager – Sustainable Transition to create value for our society based on results that will be generated by the WEL-T fundamental research programmes.

Cédric Blanpain is the winner of the Momentum Award 2023 of the International Society for Stem Cell Research (ISSCR). This is the first time that such a prestigious award has been given to a researcher based in Europe.

Miikka Vikkula is the recipient of the prestigious Earl P. Benditt Award which he will receive at the 2023 edition of the North American Vascular Biology Organization (NAVBO) meeting in Rhode Island, USA.

Alain Vanderplasschen and his team demonstrated a key role for the Zalpha protein domain of Cyprinid herpesvirus 3 in the mechanism of viral infection in carp.  

Sophie Lucas’ team showed that the strategy of blocking GARP, a novel immuno-oncology target under clinical investigation for solid cancers, also has potential in "liquid" tumours.